DIGITAL HEALTHCARE

Airrosti and Luna Partner to Improve Access for Musculoskeletal Care providing virtual care solution

Luna | November 11, 2021

Airrosti and Luna Partner to Improve Access for Musculoskeletal Care providing virtual care solution

Luna, the leading provider of on-demand physical therapy, today announced a partnership with Airrosti, a national provider of high-quality, outcome-based musculoskeletal (MSK) care, to offer in-person, at-home physical therapy services to complement the Airrosti Remote Recovery (ARR) virtual care solution. Using Luna's in-person, on-demand physical therapy services platform, Airrosti can immediately expand access to convenient, high-quality, at-home care for patients in the 46 states currently covered by ARR.  

The primary challenge faced by purely digital MSK offerings today lies in care coordination. No two patients are alike, and while many respond well to a virtual clinic experience, others require in-person care. However, for many patients, travelling to a clinic consistently for an extended period is inconvenient––or even impossible. For these patients and in markets where Airrosti doesn't have clinics, the Airrosti and Luna partnership is particularly important.

"As a provider group who is delivering care nationally, we needed a partner solution to best serve our virtual patients that may require in-person conservative care or physical therapy," said Chris Cato, D.C., chief population health officer for Airrosti. "This alliance with Luna provides timely and efficient access to high-quality care that improves clinical efficacy and drives better outcomes. And, from a service delivery standpoint, this relationship significantly enhances Airrosti's ability to rapidly ramp up in-person service in new markets as requested by our carrier and employer partners."  

As an extension of Airrosti Remote Recovery, patients will gain the opportunity to use Luna's technology platform to request an appointment and then be matched to a local therapist based on specialty, geography, schedule, and other factors. Through the Luna partnership, ARR patients can expect:

  • To begin treatment within 48 hours of referral
  • In-person delivery at the patient's home, gym, or office
  • 45 to 55 minutes of dedicated 1:1 time with a licensed physical therapist per visit
  • Comprehensive MSK treatment––Luna's model of care supports 87%+ of all patients needing outpatient physical therapy
  • A 50% higher adherence rate than in-clinic PT visits

"Airrosti recognizes that virtual care––and especially physical therapy––requires a customized, patient-centric approach to help improve outcomes. The hybrid virtual/in-person model made possible by this partnership will not only expand access to safe, convenient, high-quality care for more people nationwide, but will help ensure that more patients complete their PT regimens and regain the quality of life they need."

Palak Shah, co-founder and head of clinical operations at Luna

To learn more about Airrosti's virtual MSK offerings, visit the Remote Recovery resource page. For more information on how Luna helps clinics expand the reach and profitability of their operations, visit the Physical Therapy Practices resource page.

About Airrosti
Airrosti Rehab Centers (Airrosti), is a national health care group that employs and trains skilled providers who specialize in delivering high-quality, outcome-based musculoskeletal care, both in person and virtually through their digital healthcare solution, Airrosti Remote Recovery (ARR). Airrosti Remote Recovery is the only virtual MSK solution supported by a provider group with over 1 million patient outcomes and 17 years of clinical experience. The company's strict adherence to quality care standards across its provider network significantly reduces costs and recovery times for patients and prevents unnecessary MRIs, pharmaceuticals, and surgeries. Many patients experience significant improvement in pain, range of motion, and a return to normal activity, often within only three visits (Based on patient-reported outcomes). Airrosti is currently available in 46 states including the District of Columbia and has over 200 brick-and-mortar locations across Texas, Virginia, Ohio, and Washington. 

About Luna
Luna is the leader in on-demand physical therapy, delivering outpatient physical therapy beyond the four walls of a clinic. For patients, Luna has reimagined the physical therapy experience, matching them with a therapist for in-person care at the time and location of their choosing and ongoing coaching through an easy-to-use app. For physical therapists, Luna enables them to manage their careers with flexibility and autonomy, using a platform that makes scheduling efficient, documentation easy, and billing automatic. Luna is the fastest growing in-person physical therapy provider, with more than 1,200 exceptional therapists providing services in 20 states across the United States.

Spotlight

(SPONSORED) Learn more about Verizon’s support of initiatives, such as Girls Who Code and the Inspire Her Mind campaign. Helen Donnelly of Verizon also describes the organization’s goals with respect to women in health IT.


Other News
HEALTH TECHNOLOGY

Microbot Medical Announces Strategic Collaboration with Stryker Corporation to Develop the LIBERTY® Robotic System for Neurovascular Applications

Microbot Medical | December 28, 2021

Microbot Medical Inc.announced that it has entered into a strategic collaboration agreement with Stryker, a leading global medical technology company. The company will collaborate with Stryker’s Neurovascular division to integrate its neurovascular instruments with Microbot’s LIBERTY Robotic System to develop the world’s first dedicated robotic procedural kits for use in certain neurovascular procedures. “We have already ensured that the LIBERTY Robotic System has a strong and sustainable competitive advantage, and the collaboration with Stryker will allow us to further expand in the neurovascular space. I believe the similarities in our innovation culture, as well as our complementary core capabilities, will allow us to establish a truly differentiated solution that will benefit all stakeholders and accelerate our goal of changing the way robotic surgery is viewed and adopted.” Harel Gadot, Chairman, CEO and President of Microbot Medical The company will continue to develop the LIBERTY Robotic System independently for use in peripheral and coronary procedures. The animal feasibility studies to date support the company’s assertion that it will potentially allow physicians to safely and efficiently conduct remote catheter-based vascular procedures, and reduce the risk for radiation exposure, physical strain on the user and Hospital Acquired Infections (HAIs), without the need for cumbersome and expensive capital equipment. About Microbot Medical Microbot Medical Inc.is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP). Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies.

Read More

HEALTH TECHNOLOGY

The GIANT Health Event 2021. Early bird tickets on sale now

GIANT Health | October 13, 2021

Europe's greatest festival of Health Tech Innovation | 30th Nov - 1st Dec 2021 Join us at GIANT this year and immerse yourself in Europe's greatest festival of healthcare innovation. Find inspiration from global leading innovators, and discover the advances in technology that are revolutionizing healthcare provision. GIANT 2021 is set to be our biggest event yet so don't miss out. GIANT Health event is an invaluable, cost-effective global hybrid event. Combining both a real-world physical trade show and multiple conferences in central London, as well as a sophisticated and engaging virtual event based on GIANT Health’s proprietary Virtual Event Platform. Learn more about Digital Therapeutics.Would you like to network with 1000s and 1000s of Europe's leading healthcare and technology innovators, hospital leaders, health-sector investors, and entrepreneurs?Over 400 speakers will convene in 15+ conference at the massive GIANT Health Event, 30 November - 1 December, 2021. Come join us in person or remotely.Early Bird tickets are now available. CLAIM YOUR TICKET HERE A special promotional code which allows to save up to 25% on top is available for our subscribers: MEDIA25 See you there! Media contact: GIANT Health Events Ltd Olga Nosova +44 20 8144 9779 Olga@GIANT.health

Read More

HEALTH TECHNOLOGY

Dura Software Acquires Leading Cloud-Based Telehealth Software Platform SecureVideo

Dura Software | January 20, 2022

Dura Software, specialists in acquiring and operating hyperniche software products, announced it has acquired SecureVideo, a cloud-based software company with extensive experience developing a secure SaaS telehealth platform for the healthcare industry. Expanding the Dura portfolio, SecureVideo is the ninth acquisition for Dura Software and furthers the Dura mission of acquiring niche software companies that serve critical business needs. "We are excited to welcome SecureVideo into the Dura portfolio of companies. Jonathan Taylor and his team have created a highly scalable SaaS solution that enables a loyal group of physicians and practitioners to serve their patients safely and effectively every day. SecureVideo has a seasoned team that understands the healthcare market and how to best leverage technology to make the lives of healthcare professionals and patients easier. " Paul Salisbury, CEO of Dura Software Serving the healthcare industry, SecureVideo produces a HIPAA-compliant, cloud-based telehealth platform designed to aid clients with quickly mastering their telehealth workflow. During 2020, SecureVideo's usage grew significantly, expanding to 30 times its typical usage, prompting the company to quickly scale its operations while it successfully met the growing needs of new and existing customers. As a trusted partner in the healthcare space, SecureVideo provides a flexible, reliable telehealth technology solution to behavioral health organizations, medical groups, hospitals, physician offices, specialty healthcare organizations and other medical organizations. The CEO of SecureVideo, Jonathan Taylor, will lead the company as it transitions into the Dura Software portfolio of companies. "The acquisition of SecureVideo by Dura Software will provide the resources and expertise we need to scale our product capabilities, customer support, and market reach well beyond what would have otherwise been possible," says Taylor. "With Dura's assistance, the company will be able to rapidly add important features and functionality to our world-class product, amplify our customer-first culture, and expand our customer footprint, all while maintaining the high standard of excellence we have always worked to achieve." Based in Alameda, California, SecureVideo will move its headquarters to San Antonio, while all employees will remain in their current locations. About Dura Software Dura Software is an expert in acquiring, owning and operating "Hyper-Niche" software businesses. Over the coming years, Dura will continue to expand by acquiring additional great businesses and by generating sustained profitable growth from business operations. Dura Software is based in downtown San Antonio and operates a portfolio of companies that includes 6Connex, DB Technology, Lane, DVSAnalytics, Eventory, Moki, NordicIT and Vertex Systems.

Read More

HEALTH TECHNOLOGY

Alkem Laboratories Ltd. to Launch State of the Art Technology for Diabetic Foot Ulcer Management

Alkem Laboratories Ltd. | January 13, 2022

Alkem Laboratories Ltd. (Alkem) hereby announces to launch a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India. The solution would be based on disruptive 4D Bioprinting technology, which would be used to treat deep, non-healing chronic wounds and is expected to be launched in the Indian market in the latter half of 2022 post regulatory approval. This advanced technology for DFU management has a high scope of preventing amputations in diabetic patients. This technology will be available at affordable rates to Indian patients at a time when there is no definitive treatment for DFU in India. India currently has approximately 77 mn diabetes patients, the second highest in the world. A diabetic foot ulcer is one of the most significant and devastating complications of diabetes and is defined as a foot affected by ulceration that is associated with neuropathy and/or peripheral arterial disease of the lower limb in a patient with diabetes. Approximately, 12-15% with diabetes suffer from DFU at least once in a lifetime. 5–24% of them will finally lead to limb amputation within 6–18 months after the first evaluation. The risk of foot ulceration and limb amputation increases with age and the duration of diabetes. Alkem has collaborated with Rokit Healthcare Inc. to commercialize the technology in India to help reduce amputation amongst DFU patients considering the negative impact of amputation on a patient's quality of life and the associated economic burden on the healthcare system. "In India, Diabetes is one of the major healthcare challenges. The challenge in itself is so huge that diabetic foot ulcers often get ignored. Approximately 1 lac people have to undergo amputation every year and compromise on their quality of life. To address the problem, Alkem has collaborated with Rokit Healthcare Inc., a global regenerative solutions company, to bring out novel solutions for the management of diabetic foot ulcers." Mr. Sandeep Singh, Managing Director, Alkem Laboratories Ltd Adding further, Mr. Sandeep asserted, "Alkem, over the years, has always been at the forefront in delivering high-quality patient care, through its innovation and patient-centric initiatives." About Alkem Laboratories Ltd Established in 1973 and headquartered in Mumbai, Alkemis a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales. The Company also has presence in more than 40 international markets, with the United States being its key focus market.

Read More